Clinical trials: Glucagon
Kidney Disease, Chronic, Diabetes
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population.
- Conditions
- Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)
- Trial name
- GUARD-1 (NCT07017270)
- Testing
- Semaglutide Pen
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Unity Health Toronto
Diabetes
Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans
The aim of this proposal is to dissect the mechanisms controlling gastric emptying, appetite and food intake in humans, and to obtain new knowledge to fight obesity on a pharmacological basis.
- Trial name
- NCT00876213
- Where
- Denmark
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Obesity
Breakfast Intake and Satiety Hormones
The experiments in this study will assess if while following a reduced energy diet, eating a breakfast with higher protein quality will enhance weight loss compared to another breakfast with lower protein quality, but matched for…
- Trial name
- NCT02497859
- Testing
- Egg Breakfast (EB), Cereal Breakfast (CB), Weight Loss Counseling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Texas Tech University
Type 1 Diabetes
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
Aim: To investigate the glucagonostatic effect of glucagon-like peptide-1 (GLP-1) independent of the gastric emptying rate.
- Trial name
- ALFA-1 (NCT02584582)
- Testing
- Liraglutide, Exenatide, Liquid meal test
- Volunteers
- 10 people
- Sponsor
- Hvidovre University Hospital
Type2 Diabetes
Effect of GIP After a Meal in Patients With Type 2 Diabetes
The aim of this study is to investigate the effects of antagonising GIP after a meal on plasma levels of glucagon. 10 participants are going through four experimental days each, where they ingest a meal and afterwards receive…
- Trial name
- GA-7 (NCT03702660)
- Testing
- GIP(3-30)NH2, Peripheral venous cannulation, GLP-1
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Drug Overdose, Overdose of Beta-adrenergic Blocking Drug
Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition
This trial investigates effects of a glucagon bolus injection on heart rate, blood pressure and cardiac output during beta-blocker-induced cardiodepression.
- Trial name
- GLUCAGON (NCT03533179)
- Testing
- Glucagon, Esmolol, Physiologic saline - glucagon dummy
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying
GLP_1 RA Ultrasound Study
The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes
- Trial name
- NCT06581120
- Testing
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Type 1 Diabetes
Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improved glycemic control vs. usual in the outpatient environment.
- Trial name
- NCT01762059
- Testing
- Bi-homonal Bionic Pancreas, Usual care
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Glucose Metabolism, Glucagon
Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants
In this study the investigators will investigate the acute effects of increasing glucagon exposure on metabolic parameters in healthy participants. Participants will participate in one study day.
- Trial name
- NCT06921824
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Familial Renal Glucosuria, Diabetes Mellitus
Human Solute Carrier Family 5 Member 2 (SLC5A2) Deficiency and the Glucagon-Incretin Axis
Sodium-glucose-cotransporter 2 (SGLT2) are a new type of oral antidiabetic drugs. SGLT2 inhibitors increase the urinary glucose excretion and thereby decrease blood glucose levels.
- Conditions
- Familial Renal Glucosuria, Diabetes Mellitus, Cardiovascular Diseases
- Trial name
- NCT03965000
- Testing
- Mixed-meal-tolerance-test
- Where
- Austria
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Residual Gastric Contents, Pulmonary Aspiration of Gastric Contents
Effect of Fasting Recommendations Among Patients Using GLP-1 Receptor Agonists
The aim of this randomised controlled trial is to determine the effect of a 24-hour clear liquid diet compared to standard fasting guidelines on the proportion of participants who present with increased residual gastric contents…
- Trial name
- NCT06839248
- Testing
- 24-hour clear liquid diet, Standard fasting guidelines
- Where
- 2 sites in Australia
- Volunteers
- 154 people
- Sponsor
- St Vincent's Hospital Melbourne
Healthy
A Pilot Study to Evaluate the Glucagon-Like Peptide 1 Response to the Challenge of Mixed Meals in Chinese Subjects
The purpose of the study is to standardize a meal test to facilitate future studies of the postprandial glucagons-like peptide 1 (GLP-1) response in Chinese subjects.
- Trial name
- IC-1-V1 (NCT00884091)
- Where
- Taiwan
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Congenital Hyperinsulinism
GLP-1 Receptor Expression in CHI
The primary objective is the in vivo and ex vivo investigation of the expression and distribution of the GLP-1R in the pancreas of CHI patients.
- Trial name
- GLP-1-CHI (NCT03768518)
- Testing
- 68Ga-exendin-4 PET/CT
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Diabetes Mellitus, Type 1
GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
The purpose of this study is to test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes.
- Trial name
- PHROG (NCT04432090)
- Testing
- Study Medication (MBX-2982), No medication for this group
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Multiple Sclerosis
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not.
- Trial name
- NCT07207148
- Testing
- GLP-1, Ocrelizumab (US)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northwestern University
Overweight
Carbohydrates and Gut Hormones After Gastric Bypass Surgery
To investigate the secretion of gut hormones, in particular glucagon-like peptide 1 (GLP-1), after ingestion of glucose and fructose as separate monosaccharides or combined in the disaccharides sucrose and isomaltulose and the…
- Trial name
- NCT02879955
- Testing
- Glucose + Fructose, Sucrose, Isomaltulose
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Type 2 Diabetes, Microvascular Dysfunction
Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.
The purpose of the study is to determine if a GLP-1 agonist improves microvascular perfusion in the heart of patients with type 2 diabetes
- Trial name
- EGOFIP (NCT01931982)
- Testing
- Victoza
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Bispebjerg Hospital
Diabetes Mellitus, Type 1
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia…
- Trial name
- NCT03556098
- Testing
- glucose-dependent insulinotropic peptide, Glucose-Dependent Insulin-Releasing Hormone[3-30], Saline Solution
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Steno Diabetes Center Copenhagen
Spinal Cord Injuries, Insulin Resistance
Once Weekly GLP-1 in Persons With Spinal Cord Injury
Chronic spinal cord injury (SCI) results in adverse soft tissue body composition changes and an extremely sedentary lifestyle. These abrupt changes often lead to a high prevalence of cardiometabolic diseases, such as impaired…
- Conditions
- Spinal Cord Injuries, Insulin Resistance, Pre Diabetes, Obesity
- Trial name
- NCT03292315
- Testing
- Semaglutide 1MG Injection [Ozempic], No Intervention
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Diabetes Type 2
"Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients"
The purpose of this study is to demonstrate the secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets with different nutritional compounds (fat, protein and carbohydrate food) in drug näive…
- Trial name
- NCT00881543
- Testing
- Dipeptidyl Peptidase IV inhibitors
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- University of Sao Paulo General Hospital